Alzamend NeuroALZN
13F holders, Q2 2025 (June 30)7holders
$2.91avg. 13F price*
At the end of Q2 2025, 7 institutions reported holding Alzamend Neuro Inc. (ALZN) in their 13F filings. The largest holders were UBS Group AG ($3K), Tower Research Capital LLC (TRC) ($2K) and BlackRock, Inc. ($1K).
- Company
- Alzamend Neuro Inc.
- CUSIP
- 02262M605
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $5K |
| Exits | 0 | $0 |
Ownership 7 holders
| UBS Group AG | 0.00% | New | 902 | $3K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 797 | $2K |
| BlackRock, Inc. | 0.00% | No change | 441 | $1K |
| SBI Securities Co., Ltd. | 0.00% | Add +1001.1% | 22 | $64 |
| Bank of America Corp. | 0.00% | Add +17.2% | 19 | $55 |
| Activest Wealth Management | 0.00% | Reduce -9.9% | 2 | $6 |
| Harbor Investment Advisory, LLC | 0.00% | Reduce -55.0% | 1 | $3 |
"% of holder's portfolio" is ALZN's weight in each manager's 13F, not the share of Alzamend Neuro Inc. the manager owns.